Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05917587 · ClinicalTrials.gov registry record · Early Phase 1
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
A Early Phase 1 study of Gestational Diabetes, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05917587: Recruiting Early Phase 1 study of Gestational Diabetes, sponsored by Anna Stanhewicz, PhD.
NCT05917587 is a Early Phase 1 study of Gestational Diabetes that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 30 participants, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05917587, a Early Phase 1 study of Gestational Diabetes, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Primary Outcome
cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine
Conditions Studied
Interventions
- OTHER placebo
- DRUG Metformin Hydrochloride
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2028-06-30 |
| Phase | Early Phase 1 |
What NCT05917587 shows while recruiting
NCT05917587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Gestational Diabetes appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT05917587 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05917587 about?
NCT05917587 is a clinical study titled "Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes". The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
What is the current status of trial NCT05917587?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-09-11. Estimated completion is 2028-06-30.
What conditions does trial NCT05917587 study?
This clinical trial studies the following conditions: Gestational Diabetes.
What interventions are being tested in trial NCT05917587?
The interventions under investigation include: placebo (OTHER), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05917587?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05917587 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05917587's enrollment target sits among peer trials
30 34th of 41 higher than 7 of 41 other Gestational Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gestational Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
RECRUITING · Early Phase 1
-
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Soy Supplementation and Gestational Diabetes
COMPLETED · Early Phase 1
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI